|
1
|
Capitanio U and Montorsi F: Renal cancer.
Lancet. 387:894–906. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Eggener SE, Yossepowitch O, Pettus JA,
Snyder ME, Motzer RJ and Russo P: Renal cell carcinoma recurrence
after nephrectomy for localized disease: Predicting survival from
time of recurrence. J Clin Oncol. 24:3101–3106. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schmidinger M, Larkin J and Ravaud A:
Experience with sunitinib in the treatment of metastatic renal cell
carcinoma. Ther Adv Urol. 4:253–265. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili
R, Bjarnason GA, et al: Overall survival and updated results for
sunitinib compared with interferon alfa in patients with metastatic
renal cell carcinoma. J Clin Oncol. 27:3584–3590. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Motzer RJ, Bacik J and Mazumdar M:
Prognostic factors for survival of patients with stage IV renal
cell carcinoma: Memorial sloan-kettering cancer center experience.
Clin Cancer Res. 10:6302S–6303S. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rini BI, Escudier B, Tomczak P, Kaprin A,
Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME,
Rusakov IG, et al: Comparative effectiveness of axitinib versus
sorafenib in advanced renal cell carcinoma (AXIS): A randomised
phase 3 trial. Lancet. 378:1931–1939. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hutson TE, Escudier B, Esteban E,
Bjarnason GA, Lim HY, Pittman KB, Senico P, Niethammer A, Lu DR,
Hariharan S and Motzer RJ: Randomized phase III trial of
temsirolimus versus sorafenib as second-line therapy after
sunitinib in patients with metastatic renal cell carcinoma. J Clin
Oncol. 32:760–767. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hainsworth JD, Rubin MS, Arrowsmith ER,
Khatcheressian J, Crane EJ and Franco LA: Pazopanib as second-line
treatment after sunitinib or bevacizumab in patients with advanced
renal cell carcinoma: A Sarah Cannon Oncology Research Consortium
Phase II trial. Clin Genitourin Cancer. 11:270–275. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Motzer RJ, Escudier B, Oudard S, Hutson
TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA,
Hollaender N, et al: Efficacy of everolimus in advanced renal cell
carcinoma: A double-blind, randomised, placebo-controlled phase III
trial. Lancet. 372:449–456. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gotink KJ, Rovithi M, de Haas RR,
Honeywell RJ, Dekker H, Poel D, Azijli K, Peters GJ, Broxterman HJ
and Verheul HM: Cross-resistance to clinically used tyrosine kinase
inhibitors sunitinib, sorafenib and pazopanib. Cell Oncol (Dordr).
38:119–129. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Saftig P and Klumperman J: Lysosome
biogenesis and lysosomal membrane proteins: Trafficking meets
function. Nat Rev Mol Cell Biol. 10:623–635. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kong YW, Ferland-McCollough D, Jackson TJ
and Bushell M: microRNAs in cancer management. Lancet Oncol.
13:e249–e258. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Slaby O, Jancovicova J, Lakomy R, Svoboda
M, Poprach A, Fabian P, Kren L, Michalek J and Vyzula R: Expression
of miRNA-106b in conventional renal cell carcinoma is a potential
marker for prediction of early metastasis after nephrectomy. J Exp
Clin Cancer Res. 29:902010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Iwamoto H, Kanda Y, Sejima T, Osaki M,
Okada F and Takenaka A: Serum miR-210 as a potential biomarker of
early clear cell renal cell carcinoma. Int J Oncol. 44:53–58. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yamaguchi N, Osaki M, Onuma K, Yumioka T,
Iwamoto H, Sejima T, Kugoh H, Takenaka A and Okada F:
Identification of MicroRNAs involved in resistance to sunitinib in
renal cell carcinoma cells. Anticancer Res. 37:2985–2992.
2017.PubMed/NCBI
|
|
16
|
Nofech-Mozes R, Khella HW, Scorilas A,
Youssef L, Krylov SN, Lianidou E, Sidiropoulos KG, Gabril M, Evans
A and Yousef GM: MicroRNA-194 is a marker for good prognosis in
clear cell renal cell carcinoma. Cancer Med. 5:656–664. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gotink KJ, Broxterman HJ, Honeywell RJ,
Dekker H, de Haas RR, Miles KM, Adelaiye R, Griffioen AW, Peters
GJ, Pili R and Verheul HM: Acquired tumor cell resistance to
sunitinib causes resistance in a HT-29 human colon cancer xenograft
mouse model without affecting sunitinib biodistribution or the
tumor microvasculature. Oncoscience. 1:844–853. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ayers D and Vandesompele J: Influence of
microRNAs and long non-coding RNAs in cancer chemoresistance. Genes
(Basel). 8:pii: E952017. View Article : Google Scholar
|
|
19
|
An X, Sarmiento C, Tan T and Zhu H:
Regulation of multidrug resistance by microRNAs in anti-cancer
therapy. Acta Pharm Sin B. 7:38–51. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhu X, Li D, Yu F, Jia C, Xie J, Ma Y, Fan
S, Cai H, Luo Q, Lv Z and Fan L: miR-194 inhibits the
proliferation, invasion, migration, and enhances the
chemosensitivity of non-small cell lung cancer cells by targeting
forkhead box A1 protein. Oncotarget. 7:13139–13152. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Merhautova J, Hezova R, Poprach A,
Kovarikova A, Radova L, Svoboda M, Vyzula R, Demlova R and Slaby O:
miR-155 and miR-484 are associated with time to progression in
metastatic renal cell carcinoma treated with sunitinib. Biomed Res
Int. 2015:9419802015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Berkers J, Govaere O, Wolter P, Beuselinck
B, Schöffski P, van Kempen LC, Albersen M, van den Oord J, Roskams
T, Swinnen J, et al: A possible role for microRNA-141
down-regulation in sunitinib resistant metastatic clear cell renal
cell carcinoma through induction of epithelial-to-mesenchymal
transition and hypoxia resistance. J Urol. 189:1930–1938. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Goto Y, Kurozumi A, Nohata N, Kojima S,
Matsushita R, Yoshino H, Yamazaki K, Ishida Y, Ichikawa T, Naya Y
and Seki N: The microRNA signature of patients with sunitinib
failure: Regulation of UHRF1 pathways by microRNA-101 in renal cell
carcinoma. Oncotarget. 7:59070–59086. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Giuliano S, Cormerais Y, Dufies M, Grépin
R, Colosetti P, Belaid A, Parola J, Martin A, Lacas-Gervais S,
Mazure NM, et al: Resistance to sunitinib in renal clear cell
carcinoma results from sequestration in lysosomes and inhibition of
the autophagic flux. Autophagy. 11:1891–1904. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gotink KJ, Broxterman HJ, Labots M, de
Haas RR, Dekker H, Honeywell RJ, Rudek MA, Beerepoot LV, Musters
RJ, Jansen G, et al: Lysosomal sequestration of sunitinib: A novel
mechanism of drug resistance. Clin Cancer Res. 17:7337–7346. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lee H, Kim KR, Cho NH, Hong SR, Jeong H,
Kwon SY, Park KH, An HJ, Kim TH, Kim I, et al: MicroRNA expression
profiling and Notch1 and Notch2 expression in minimal deviation
adenocarcinoma of uterine cervix. World J Surg Oncol. 12:3342014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Künzli BM, Berberat PO, Zhu ZW, Martignoni
M, Kleeff J, Tempia-Caliera AA, Fukuda M, Zimmermann A, Friess H
and Büchler MW: Influences of the lysosomal associated membrane
proteins (Lamp-1, Lamp-2) and Mac-2 binding protein (Mac-2-BP) on
the prognosis of pancreatic carcinoma. Cancer. 94:228–239. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Giatromanolaki A, Kalamida D, Sivridis E,
Karagounis IV, Gatter KC, Harris AL and Koukourakis MI: Increased
expression of transcription factor EB (TFEB) is associated with
autophagy, migratory phenotype and poor prognosis in non-small cell
lung cancer. Lung Cancer. 90:98–105. 2015. View Article : Google Scholar : PubMed/NCBI
|
